9TH0 Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.01
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.89M
Enterprise Value€15.81M
Total Cash (Recent Filing)€1.29M
Total Debt (Recent Filing)€8.69M
Price to Earnings (P/E)66.7
Beta-0.63
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding389,104,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)6.55
Price to Sales (P/S)1.33
P/FCF Ratio-3.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp improvement in revenue indicates stronger business scale and customer demand than in the prior period. If maintained, this growth can improve operating leverage, support investment in the business, and provide a foundation for converting the recent recovery into more durable earnings.
Gross Margin ExpansionA materially higher gross margin improves the economics of each unit of revenue and gives the company greater capacity to absorb operating costs. Sustaining this improvement would strengthen the path toward profitability and make future revenue growth more valuable to shareholders.
Cash Flow TurnaroundThe shift from negative operating and free cash flow in FY2021-FY2025 to positive TTM generation is a meaningful improvement in financial quality. Continued cash conversion could reduce reliance on external funding, support operations, and provide greater flexibility as the business scales.
Bears Say
Weak Operating ProfitabilityDespite better revenue and gross margin, the company remains loss-making at the operating level. Negative EBIT shows that overhead and other operating costs still exceed gross profit, leaving earnings vulnerable if growth slows and making the recent recovery unproven as a sustainable profit model.
Elevated LeverageLeverage has improved substantially but remains elevated relative to the company’s weak operating profitability. This reduces financial flexibility, increases sensitivity to any earnings deterioration, and may constrain the ability to fund growth or absorb setbacks without additional balance-sheet pressure.
Thin Cash CoveragePositive cash generation is encouraging, but the low coverage ratio indicates that current cash flow provides only a limited buffer against obligations. With leverage still high, the company may have less capacity to withstand weaker trading or direct cash toward strategic investment and debt reduction.
Epsilon Healthcare Limited News
9TH0 FAQ
What was Epsilon Healthcare Limited’s price range in the past 12 months?
Epsilon Healthcare Limited lowest stock price was €0.01 and its highest was €0.01 in the past 12 months.
What is Epsilon Healthcare Limited’s market cap?
Epsilon Healthcare Limited’s market cap is €4.89M.
When is Epsilon Healthcare Limited’s upcoming earnings report date?
Epsilon Healthcare Limited’s upcoming earnings report date is Feb 26, 2027 which is in 121 days.
How were Epsilon Healthcare Limited’s earnings last quarter?
Epsilon Healthcare Limited released its earnings results on Aug 31, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Epsilon Healthcare Limited overvalued?
According to Wall Street analysts Epsilon Healthcare Limited’s price is currently Overvalued.
Does Epsilon Healthcare Limited pay dividends?
Epsilon Healthcare Limited does not currently pay dividends.
What is Epsilon Healthcare Limited’s EPS estimate?
Epsilon Healthcare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epsilon Healthcare Limited have?
Epsilon Healthcare Limited has 389,104,000 shares outstanding.
What happened to Epsilon Healthcare Limited’s price movement after its last earnings report?
Epsilon Healthcare Limited reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Epsilon Healthcare Limited?
Currently, no hedge funds are holding shares in DE:9TH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Epsilon Healthcare Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
3.34%
Trailing 12-Months
Asset Growth
121.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Epsilon Healthcare Limited
Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manufacturing and distributing a range of hydroponic supplies, including equipment, materials, and vital nutrients; developing and providing medicinal cannabis products; and offering comprehensive, ready-to-implement solutions for cannabis cultivation. The company officially rebranded from THC Global Group Limited to Epsilon Healthcare Limited in February 2021.
Technical Analysis
Vita Life Sciences Limited
―
Little Green Pharma Ltd.
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―